FDA Approves Expanded Use of Vertex's Casgevy CRISPR Gene Therapy for Sickle Cell Disease in Children as Young as 2

What's happening

The U.S. Food and Drug Administration approved expanded labeling for Casgevy (exagamglogene autotemcel) on July 1, 2026, extending eligibility for the therapy to patients ages 2 years and older with sickle cell disease (SCD) accompanied by recurrent vaso-occlusive crises, or with transfusion-dependent beta thalassemia (TDT). The prior approval had been limited to patients ages 12 and older. The regulatory decision was granted through the FDA's Commissioner's National Priority Voucher program, with the agency completing its review 53 days after the companies filed their supplemental application. Casgevy, co-developed by Vertex Pharmaceuticals (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP), holds the distinction of being the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT, and remains the first CRISPR-based gene therapy to receive FDA approval.

Vertex CEO and President Reshma Kewalramani, M.D., addressed the expanded approval, stating: "Just as we redefined what is possible in cystic fibrosis, our ambition is to transform the future for people living with sickle cell disease and transfusion-dependent beta thalassemia. The remarkable consistency of results across age groups reinforces the potential of CASGEVY to deliver durable, transformative benefits to those who have historically had limited options." The pediatric expansion adds approximately 5,500 U.S. children to the pool of eligible patients, a meaningful increase relative to the addressable population under the prior age threshold.

Why it matters for markets

The pediatric label expansion directly enlarges the addressable U.S. patient population for Casgevy, a therapy that recorded $43 million in Q1 2026 revenue on CRISPR Therapeutics' reported share. Vertex, which carries primary commercial responsibility for the product, has projected combined 2026 revenue of $500 million across Casgevy and its pain therapy Journavx. The addition of approximately 5,500 newly eligible children represents a structural increase in the potential treatment pool, though the pace at which pediatric patients convert to treated patients will depend on clinical site readiness, payer coverage decisions, and the logistical complexity of administering a one-time cell therapy to younger patients.

The speed of the regulatory process is also notable from a market-access standpoint. The 53-day review timeline under the FDA's Commissioner's National Priority Voucher program is substantially compressed relative to standard supplemental biologics license application timelines, which can extend to ten months or more. For Vertex, which reported full-year revenue of $12.22 billion and carries a market capitalization of approximately $134 billion, Casgevy represents a strategic diversification beyond its core cystic fibrosis franchise. For CRISPR Therapeutics, with a market capitalization of approximately $5.92 billion, Casgevy is the company's sole approved commercial product and the primary near-term revenue driver, making the expanded label a material development for its commercial trajectory.

The approval also carries broader implications for the CRISPR gene-editing field. Casgevy's demonstrated safety and efficacy profile across age groups down to 2 years, as cited by Vertex's chief executive, may inform regulatory and clinical expectations for other CRISPR-based programs in development across the industry.

Sectors and assets to watch

The primary tickers directly affected are Vertex Pharmaceuticals (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP), the co-developers and co-commercialization partners for Casgevy. Vertex holds the broader commercial infrastructure and revenue base, with Casgevy sitting alongside its established CFTR modulator portfolio — including Trikafta, Kalydeco, Orkambi, and Symdeko — as well as the recently launched Journavx. CRISPR Therapeutics, whose pipeline beyond Casgevy includes allogeneic CAR-T programs (CTX110, CTX130) and in vivo editing therapies for oncology and autoimmune indications, derives its current commercial revenue almost entirely from the Casgevy collaboration.

More broadly, the approval is relevant to the gene therapy and cell therapy sector, where pediatric label expansions and accelerated FDA review pathways are closely monitored as indicators of regulatory posture toward advanced genetic medicines. Companies developing competing or complementary approaches to hemoglobinopathies, as well as those pursuing CRISPR-based therapies in other indications, may view this approval as a data point on the FDA's willingness to extend gene-editing therapy approvals to younger patient populations through expedited mechanisms.

What to watch next

Key developments to monitor include Vertex's disclosure of Casgevy revenue in its Q2 2026 earnings report, which will provide the first commercial data point following the pediatric label expansion, and whether the company updates or reaffirms its $500 million combined Casgevy and Journavx revenue projection for the full year. Observers should also track the rate of new treatment center activations capable of administering Casgevy to pediatric patients ages 2 through 11, payer coverage determinations for the newly eligible age cohort, and any clinical data releases from CRISPR Therapeutics' broader pipeline programs that could affect the company's revenue diversification timeline beyond its sole approved product.